← Back to Clinical Trials
Recruiting Phase 2 NCT06518616

NCT06518616 Meditation to Reduce Firefighter Distress

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06518616
Status Recruiting
Phase Phase 2
Sponsor University of Arizona
Condition Psychological Distress
Study Type INTERVENTIONAL
Enrollment 192 participants
Start Date 2024-12-03
Primary Completion 2026-08-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
10-day meditation intervention10-day health education intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 192 participants in total. It began in 2024-12-03 with a primary completion date of 2026-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The more than one million firefighters in the United States provide critical emergency medical services in communities they serve and are on the front lines of healthcare delivery, including in the post-pandemic world. As a result of exposure to occupational stressors, a high proportion of firefighters experience considerable stress-related burden including psychological distress (i.e., increased features of anxiety and depression). To address this need, this project will test the efficacy of a 10-day meditation intervention (i.e., 10 individual prerecorded audio units delivered by smartphone app) among career firefighters to decrease psychological distress (i.e., anxiety and depression).

Eligibility Criteria

Inclusion criteria: 1) currently employed as a career firefighter, 2) 18 or older, 3) speak and understand English, and 4) own a smartphone (iPhone or Android) able to download and run the intervention apps. Exclusionary factors: 1) diagnosis of an illness requiring use of corticosteroids (e.g., asthma), and 2) have ongoing or past regular meditation experience in the last 4 years (i.e. more than two meditation session \[completed or attempted\] per year either with a group or individually), as determined by the PI.

Contact & Investigator

Central Contact

Thaddeus Pace, PhD

✉ twwpace@arizona.edu

📞 5206263520

Principal Investigator

Thaddeus Pace, PhD

PRINCIPAL INVESTIGATOR

University of Arizona

Frequently Asked Questions

Who can join the NCT06518616 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Psychological Distress. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06518616 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06518616 currently recruiting?

Yes, NCT06518616 is actively recruiting participants. Contact the research team at twwpace@arizona.edu for enrollment information.

Where is the NCT06518616 trial being conducted?

This trial is being conducted at Tucson, United States.

Who is sponsoring the NCT06518616 clinical trial?

NCT06518616 is sponsored by University of Arizona. The principal investigator is Thaddeus Pace, PhD at University of Arizona. The trial plans to enroll 192 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology